In particular, loss of the TP53 response pathway has been shown to be associated with drug resistance and disease progression in RUNX1-ETO leukemia [7], while RUNX1-ETO itself was shown to activate the p53 pathway that sensitizes leukemia cells to DNA damage [8]. Here, RUNX1 is linked to leukemia.